Ra Pharmaceuticals (Ra Pharmaceuticals) EV-to-EBIT : -21.26 (As of Apr. 26, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Ra Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ra Pharmaceuticals's Enterprise Value is $2,273.94 Mil. Ra Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2019 was $-106.98 Mil. Therefore, Ra Pharmaceuticals's EV-to-EBIT for today is -21.26.

The historical rank and industry rank for Ra Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

RARX's EV-to-EBIT is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.05
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ra Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2019 was $1,956.16 Mil. Ra Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2019 was $-106.98 Mil. Ra Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2019 was -5.47%.

Ra Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Ra Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ra Pharmaceuticals EV-to-EBIT Chart

Ra Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

EV-to-EBIT

Get a 7-Day Free Trial

-7.78

-2.22

-8.37

-18.29

Ra Pharmaceuticals Quarterly Data
	Dec14	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
EV-to-EBIT	Get a 7-Day Free Trial														-8.37	-10.89	-14.45	-9.62	-18.29

Competitive Comparison of Ra Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Ra Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ra Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ra Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ra Pharmaceuticals's EV-to-EBIT falls into.

Ra Pharmaceuticals EV-to-EBIT Calculation

Ra Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2273.940	/	-106.98
	=	-21.26

Ra Pharmaceuticals's current Enterprise Value is $2,273.94 Mil.
Ra Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-106.98 Mil.

Ra Pharmaceuticals (NAS:RARX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ra Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2019 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2019 )	=	EBIT	/	Enterprise Value (Q: Dec. 2019 )
	=	-106.98	/	1956.15846
	=	-5.47 %

Ra Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2019 was $1,956.16 Mil.
Ra Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-106.98 Mil.

Ra Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ra Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ra Pharmaceuticals (Ra Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ra Pharmaceuticals Inc (NAS:RARX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

87 Cambridge Park Drive, Cambridge, MA, USA, 02140

Website

http://www.rapharma.com

Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level.

Executives

Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Edward T Mathers	director	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Timothy R Pearson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Aoife Brennan	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Douglas A Treco	director, officer: President and CEO	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Rajeev M. Shah	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander Cumbo	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Robert Heft	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Patrick J Kerins	10 percent owner
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David Charles Lubner	officer: Executive VP and CFO	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472